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Abstract
There have been significant advancements in the research of pancreatic islet 
transplantations over the past 50 years as a treatment for Type 1 Diabetes Mellitus 
(T1DM). This work has resulted in hundreds of clinical islet transplantation pro-
cedures internationally. One limitation of the procedure includes effective storage 
techniques during donor-recipient cross-matching following islet isolation from 
deceased donor. Cryopreservation, which is heavily used in embryology research, 
has been proposed as a prospective method for pancreatic islet banking to bridge 
the temporal intervals between donor-recipient matching. The cryopreservation 
methods currently involve the freezing of islets to subzero (−80/−196°C) tempera-
tures for storage followed by a thawing and warming period, which can be increas-
ingly harmful to islet viability and insulin secretion capabilities. Recent advances 
in islet cryopreservation technologies have improved outcomes for islet health and 
survivability during this process. The aim of this chapter is to characterize aspects 
of the islet cryopreservation method while reviewing current procedural improve-
ments that have led to better outcomes to islet health.
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1. Introduction
Pancreatic islet transplantations are currently used in human clinical studies 
to treat Type 1 Diabetes Mellitus (T1DM); however, one of the major limitations 
of this therapy remains efficient and effective storage of islet prior to transplant, 
during donor-recipient cross-matching [1]. Islet cryopreservation has a distinctly 
vigorous research history as the storage, transportation, and overall preservation 
are critical steps in islet transportation. The first human islet allotransplantation 
took place at the Washington University in the 1980s, which provided proof of 
insulin independence following the procedure [2]. Following these early successes, 
clinical trials at the University of Pittsburgh observed further prolonged insulin 
independence using an improved steroid-free immunosuppressive regimen [3]. 
These initial clinical islet transplantations demonstrated the need for a preservation 
process to bridge a temporal gap between islet isolation from donor and transplan-
tation of islet graft into recipients. In 1989, clinical trials at the University of Alberta 
were able to use both freshly isolated islets supplemented with cryopreserved islets 
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in two T1DM patients, which resulted in partial graft function [4]. The interna-
tional trial on Edmonton protocol reported success after some of over 43 Type 1 
diabetic patients achieved either partial or complete insulin independence for up 
to 3–5 years post-transplantation [5, 6]. After the establishment of the Edmonton 
protocol, the Clinical Islet Transplantation Registry (CITR) has recorded more than 
1500 human islet allotransplant recipients, which is projected to increase steadily in 
the future [7]. The Edmonton method of islet isolation was shown to improve islet 
survival during islet cryopreservation as well. A study comparing cryopreserved 
islets before the establishment of the Edmonton protocol to human islets treated 
via Edmonton method observed a 24-hour survival rate increase of 19.3% (50.1 
versus 69.4% respectively) with added increases recorded after 7 days of culture [8]. 
Although the impact of the Edmonton protocol on cryopreservation is significant, 
there is still vast room for improvement in the islet cryopreservation process.
A major problem of the transplantation field is the lack of human donors’ 
sources; the islet transplantation process is particularly hard-hit from this problem 
since each transplant recipient must be infused with islets from multiple pancre-
ases [9]. One recipient may also require multiple infusions of donor islets, which 
can further strain the donor source [10, 11]. With the epidemiologic increase in 
IDDM diagnosis, islet allotransplantation islet supply will be increasingly strained 
by the growing demand for islet replacement therapy with projected increases in 
the population of IDDM individuals [12]. The islet donor supply problems can be 
partially addressed from improvements in human islet yield, purity, and function. 
Although an average human cadaveric pancreas contains over 1 million islets, the 
human islet isolation process can be especially harsh on the isolation yield resulting 
in loses of up to 50% depending on the degree of success of the isolation [13, 14]. 
Cryopreservation techniques have been employed to address some of these islet 
isolation and preservation issues before islets are implanted into the recipient.
The human islet isolation and culturing process involves several steps that 
vary in temperature, each of which has its own benefits and deficits regarding 
the health of the islets [13]. Islet procurement from a whole donor pancreas first 
exposes islet to 4°C (histidine-tryptophan ketoglutarate solution) during sterile 
transportation to an approved clinical islet center. During the pancreas digestion 
and purification, the islets are exposed to varying temperatures between 4°C and 
room temperature. Preservation of islet currently involves the cooling of isolated 
islets in a temperature-regulated solution at 4°C prior to culturing as prolonged 
warm-ischemia will increase islet death and subsequent decrease in islet yield 
[13, 15, 16]. The final step of islet preparation involves a 24- to72-hour culture 
in approved islet media at 37°C, which has been shown to improve islet yield 
and functions with reductions in dead/apoptotic islet cell mass [17, 18]. Isolated 
human islets are preserved while donor islets of similar cross-matching biocom-
patibility are compiled and matched to an islet recipient [13]. During this critical 
time period, cryopreservation has been suggested as a preservation method for 
use during the pre-transplantation period to improve islet health. Improvements 
in the islet cryopreservation field can translate directly to improvements in 
human islet cyro-banking as well. This book chapter outlines the history of islet 
cryopreservation, current techniques in freezing/thawing periods, and cryopro-
tective additives.
1.1 History of islet cryopreservation
Following the discovery of the microscope, Spallanzani observed that sperm 
could maintain mobility even when exposed to cold temperature conditions in 
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1776 [19]. Research into the effects of cryopreservation on live tissue had its roots 
in late 1800s when scientists used this technology to preserve both spermatozoa 
and red blood cells (RBCs). During this time, research demonstrated weaknesses 
in the process which caused inconsistent results and frequent infertility caused by 
early embryonic death. A breakthrough occurred in the 1950s when James Lovelock 
discovered that the cryopreservation process caused osmotic stress in the cell by 
instantly freezing the liquid and causing the formation of ice crystals in RBCs. In 
1963, Mazur et al. were able to characterize that process when they demonstrated 
that the rate of temperature change within a cell-containing medium controlled 
the movement of water across a cell membrane and thus the degree of intracellular 
freezing [20]. This together helped to improve the overall understanding of the 
mechanism associated with the cryoprotective process. During the 1980s, research 
surrounding the cryopreservation process revealed that the speed at which the 
freezing and thawing process occurred was the most important factor in determin-
ing the survivability of the cells [21, 22]. It was demonstrated that small, slow incre-
ments in both the freezing and thawing processes prevented the rapid formation of 
ice crystals and increased membrane-bound solutes associated with early cell death 
[23]. Another initial advance in cryopreservation occurred in the late 1940s when 
researchers discovered that the use of glycerol as a medium increased the surviv-
ability of spermatozoa in subfreezing (−70°C) temperatures [24]. Using glycerol as 
a medium effectively served to protect the cells from rapid formation of ice crystal 
during the preservation process. A commonly used cyroprotective agent currently 
employed is dimethyl sulfoxide (DMSO), which is added to cell media prior to the 
freezing process [25, 26]. DMSO (10%) when added to the cell media, commonly at 
2 M concentration, increases the porosity of the cellular membrane, which allows 
water to flow more freely through the membrane [27, 28]. In addition, early research 
has demonstrated that nucleation is another way to prevent the rapid formation 
of ice crystals during freezing [28, 29]. During the freezing process, a metal rod 
supercooled with liquid nitrogen is applied to the meniscus of the medium contain-
ing islets wherein the liquid molecules begin to nucleate. These nucleation reactions 
are due to the release of latent heat of fusion from the medium, which causes the 
temperature to decrease more homogenously.
During the 1970s, cryopreservation technology was applied to rat islet preser-
vation in both storage and transportation, which demonstrated maintenance of 
high viability and function, which showed no significant difference when com-
pared to non-treated islets [30, 31]. In one study, T1DM rats received allogeneic 
islet transplants cryopreserved using 2 M DMSO (Freezing rate = 0.25°C/min; 
Thawing rate = 7.5°C), which caused normoglycemia for up to 3 months (Figure 1). 
Additionally, when a modified cryopreservation protocol was applied to canine 
allotransplantations (freezing rate = 0.25°C/min; thawing rate = 3.4°C/min),  
T1DM canine recipients demonstrated prolonged glycemic control for up to 18 
months [32]. These results highlighted the potential use of cryopreservation for 
islet transplantations in both small and large animal models in addition to dif-
ferences required when cryofreezing small and large animal pancreases. Recent 
advances in islet quality control like oxygen consumption rate (OCR), qPCR, and 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay allow 
researchers to study islet cryopreservation technology more effectively [33]. Islet 
cryopreservation research is a very active research topic with many studies aim-
ing to characterize and improve cryopreservation freezing/thawing processing, 
benefits of potential cyroprotective additives, and the effects of encapsulation on 
islet function during cryopreservation. The following section will discuss the islet 
cryopreservation process (Figure 2).
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2. Characteristics of the islet cryopreservation process
2.1 Background
A crucial aspect of cryofreezing islets is the rate of freezing and thawing, which 
can have major effects on the islet health and morphology. The freezing process 
describes the process of cooling the islet-containing medium to around −196°C.  
If the freezing process is done too rapidly (>0.25°C/min), the liquid in the medium 
will freeze too quickly and crystal ice structure will form within cell membranes. 
Conversely, if the freezing process is performed too slowly (<0.1°C/min),  
then innate/adaptive immune cells, such as macrophages, dendritic cells, and 
lymphocytes which are present within the islet medium survive in greater numbers 
and can contribute to foreign body response (FBR)-mediated graft rejection upon 
transplantation [3, 34]. Taylor et al. demonstrated increase in macrophage viability 
(91%) cryofreezing is done at a rate of 0.1°C/min compared to 72–75% viable 
macrophage when the rate between 0.1–20°C/min [35]. Therefore, a key aspect of 
cryofreezing is the use of an optimal freezing rate based on islet type and volume 
to prevent ice crystal formation and immune cell survival. Over the years, many 
studies have described varying optimal freezing rates, which has made it difficult 
to compare between freezing/thawing methods. A consistent freezing/thawing 
Figure 1. 
Sample image of encapsulated human islets stained with dithizone for 15 min, taken at 2× magnification with 
objective lens 20/40 PH. Scale bar represents 2 mm. Imaging performed at UCI laboratory under supervision of 
Dr. Jonathan Lakey PhD.
Figure 2. 
Flowchart of cryopreservation. This chart describes the range of temperature, rate of temperature change, and 
the procedure involved during cryopreservation.
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protocol uses slow freezing from −40 to −196°C followed by a rapid thawing 
starting from −196°C [36]. An early study aimed at characterizing differences 
between cooling and thawing rates exposed islets to several freezing rates between 
0.3 and 100°C/min and thawing rates of 10 or 50°C/min. Highest survival rates 
were detected at 0.3°C/min rate with slight decreases observed between 60 and 
1000°C/min rates [37]. The study also demonstrated the critical nature of using 
DMSO as a medium to protect the islet viability and function from cooling process. 
Cyroprotective agents (CPAs) like DMSO are neutral solutes of both low toxicity 
and molecular weight that replace up to 30% of the cell water and provide optimal 
conditions for subzero temperatures [38]. While a variety of DMSO concentrations 
have been tested, the most popular one used is 2 M DMSO, which is added in a 
stepwise fashion (1 M DMSO to 2 M DMSO) during pre-freezing [36]. One study 
found that when islets were exposed to 1 M DMSO for 30 min followed by incuba-
tion in 2 M DMSO for 10 min before cooling phase, then the islet insulin secretory 
patterns were improved after thawing [39]. More recently, studies have shown that 
the rate of cooling is much less important than the use of cryoprotective additives 
during the pre-freezing phase [36, 39].
2.2 Vitrification
The process of exposure and equilibration of permeating cyroprotective 
additives to islets is known as vitrification, which was first described by Rall 
et al. [38, 40]. While the use of CPAs reduces the risk of rapid ice crystal for-
mation during the cooling phase, cryoprotective agents, such as DMSO and 
ethylene glycol, have been shown to be toxic to islet viability and function 
when concentrated in the medium [38, 41, 42]. Vitrification is used to slow the 
exposure of islets to CPAs by adding the CPAs in a stepwise fashion, usually in 
ascending concentrations of CPA, thereby allowing the CPAs to slowly perme-
ate and form a solute equilibrium across the cell membrane. The vitrification 
process also causes water to flow extracellularly where, during cooling, vitreous 
water crystals slowly form outside the islet cells [38]. This vitreous medium 
exists in a solid-liquid transition state that is maintained at a supercooled tem-
perature (≤100°C), thus having the structure of a liquid but behaving mechani-
cally like a solid [43]. In addition to reducing ice crystal formation, vitrification 
involves exposing the CPAs in a stepwise fashion (1 M DMSO followed by 2 M 
DMSO), thus reducing the toxicity of the CPAs as the cooling process proceeds. 
Once the cooling process is finished, the cryopreserved islets will be stored at 
−196°C liquid nitrogen freezer until use.
2.3 Thawing
When the supercooled islet is in −196°C storage, the vitreous medium is still 
locked in a liquid-solid transition state; however, once the warming process 
begins, there is risk of ice recrystallization within the medium, which can damage 
the islets [36, 43]. A widely accepted procedure includes the use of rapid thaw-
ing from −196°C at a rate of 150–200°C/min. Mechanical agitation is applied 
to thawing samples in a 37°C water bath until all ice is gone (0°C). At 0°C, the 
samples are then placed in an ice slush bath (0°C) until thawing is completed [36]. 
Following the warming phase, it is important to remove the cryoprotectant from 
the medium. After thawing is complete, samples are spun down at 1500 RPM and 
supernatants containing most of the cryoprotectants are removed. The pellet is 
then resuspended in an isotonic buffer (0.75 M sucrose) to dilute out the remain-
ing CPAs.
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3. Factors that affect islet cryopreservation process
3.1 Background
While the use of CPAs is a critical step, there are several factors that play a 
significant role in the success of an islet cryopreservation process. Technological 
advances in these areas can help reduce the stress of the process on the islets while 
more effectively processing the islets tissue during cryopreservation.
3.1.1 Oxygen treatment
Changes in ambient atmospheric oxygen concentration can have a negative 
effect on islet viability and function via ATP metabolite depletion. In hypoxic 
conditions, β-cells are put under oxidative stress followed by ROS production, 
which facilitates islet death [44]. The thawing and rewarming phases have been 
shown to place hypoxic-related oxidative stress on cryopreserved tissues [45]. 
During the thawing/rewarming period, as islets are brought back from sub-
freezing temperature, cellular enzymes begin to function and increase oxygen 
consumption. This process can cause a reduction in adenosine 3-phosphate 
(ATP), a cellular metabolite, which can lead to islet death [45]. To address this 
issue, researchers hypothesized that hyperbaric conditions might improve islet 
recovery. Human islets were exposed to both normal oxygen conditions (21% O2, 
74% N2, and 5% CO2) and hyperbaric conditions (50% O2, 45% N2, and 5% CO2) 
at 22°C for 45 min followed by 37°C for 45 min. Short-term (post-rewarming) 
and long-term (2-day culture) islet function analysis was conducted via GSIS, 
qPCR ischemia-gene analysis, and islet metabolism via oxygen consumption rate 
(OCR) assay. Long-term culture also compared normal and hyperbaric culture 
conditions. No significant short-term function and metabolic differences were 
observed between conditions and non-treated islets. However, the hyperbaric 
conditions were shown to suppress the increases of inflammation detected in 
untreated cryopreserved islets. Islet recovery after long-term culture was sig-
nificantly better under hyperbaric conditions and was shown to increase after 
hyperbaric 2-day culture. A recent advancement in organ oxygenation known as 
persufflation involves the perfusion of humidified oxygen into the vasculature of 
the pancreas before and after cryopreservation. This technique could potentially 
mitigate the islet loss from hypoxia and ischemia during cryofreezing, thawing, 
and rewarming phase.
3.1.2 Cryopreservation storage duration
Development of an islet tissue bank will require islets to be cryopreserved for 
long periods of time, years if necessary. Generally, islet cryopreservation stud-
ies will only cryopreserve islets for short periods of time (1–90 days) [45–47]. 
For human islet cryopreservation, the upper limit of storage duration was set 
by Fox et al. in 2015. Human islets were cryopreserved at −196°C for an average 
of 17.6 ± 0.4 years. Between 2012 and 2014, human islets were then thawed and 
warmed, after which islet electrophysiology and function were analyzed. After 
measurement of β-cell excitability via path-clamp assay, similar Ca2+-influx con-
ductance patterns were observed between cryopreserved and fresh islets [48]. 
However, insulin stimulation index was significantly lower for cryopreserved 
(1.90 ± 0.24) compared to fresh islets (9.53 ± 0.92). However, after cryopreserved 
islets were transplanted into STZ-induced mice, partial normoglycemia was 
observed for 60 days with improvements to glucose tolerance [48]. More research 
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is needed to infer a limit to cryopreservation storage duration to ensure that islets 
remain functional post-thawing.
3.1.3 Islet structure limitations
Difficulties with the cryopreservation of whole organs are partially due to the 
non-homogenous temperature distribution within the large tissue structure of 
organs. Pancreatic islets exist as a spherical cluster, with an average diameter of 
100 μm, of several thousands of cells connected by a dense network of connective 
tissue [49]. The cells that lay within the islet core are susceptible to hypoxia-related 
stress, particularly during the cryopreservation process [50, 51]. A recent study 
aimed to address this structural problem by reducing islets to single cells followed 
by cryopreservation [52]. Islets were reduced to single cells and cryopreserved with 
10% DMSO and stored at −196°C (1°C/min) for four or more weeks. After a rapid 
thawing and warming phase, islets were reaggregated at 37°C [52]. Reaggregated 
islets were recovered at a rate of 80% and had similar diameter to intact cryopre-
served islets. The viability of reaggregated islets was significantly higher than intact 
islets (80 versus 25% respectively) post-thawing. No significant differences in GSIS 
function were detected between reaggregated islets and intact islets. Upon allo-
transplantation of reaggregated islets into omentum of STZ-induced diabetic rats, 
normoglycemia was achieved in 24-hours and was sustained for 10-months. Intact 
cryopreserved islets failed to achieve normoglycemia. Graft volume necessary to 
achieve diabetic correction was lower for reaggregated islets (5–8500 IE/kg) than 
fresh islets (10–12,000 IE/kg) [52].
4. Advances in islet cryoprotective additive technology
4.1 Principles background
CPAs can be divided into two major types, namely permeating and non-
permeating additives [53]. The main difference between the two major sub-types 
is whether the substance can penetrate the intracellular space during vitrification 
[54, 55]. Since the accidental discovery of glycerol in the 1940s [24], penetrating 
CPAs, such as DMSO and ethylene glycol, have shown significant benefits for islet 
survival in many studies [36]. These penetrating cryoprotectants, usually low-
molecular weight polar aprotic solvents, penetrate the cell membrane and increase 
the inner volume of the cell. An equilibrium is reached across the cell membrane 
when the intracellular water content is lower than physiological normal range, 
thus reducing the probability of intracellular ice crystal formation [56, 57]. Non-
penetrating cryoprotective additives like saccharides, which have a large molecular 
weight, remain in the extracellular space during the freezing process [56]. A build-
up of these molecules in the extracellular space induces an osmotic gradient across 
the cell membrane, which causes water to move out of the cell. Water movement 
into the extracellular space helps to reduce the risk of intracellular ice crystal forma-
tion in addition to depressing the freezing point of intracellular water [58–60]. The 
mechanism of non-penetrating CPAs has been demonstrated to be temperature 
sensitive and suboptimal for certain cell types; therefore, penetrating CPAs have 
been traditionally favored over non-penetrating CPAs even though penetrating 
CPAs have increased the risk of toxicity [61, 62]. Recently, the integration of both 
permeating and non-permeating CPAs (e.g., DMSO with University of Wisconsin 
Solution (UW)) has shown improvements to post-cryopreservation islet recovery 
and insulin secretory behavior of islets.
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4.2 Permeating cryoprotective additives
4.2.1 Dimethyl sulfoxide (DMSO)
DMSO toxicity toward islets has been shown to be minimal at concentrations 
used during the freezing phase and has even demonstrated protective capabilities 
against selective β-cell necrosis antagonist alloxan [38, 41, 63]. DMSO is considered 
the gold standard in islet cryoprotective additives and has been heavily used in 
research for the prevention of intracellular ice crystal formation. A 1999 study 
sought to compare the effect of DMSO-mediated cryopreservation on the recovery 
and function of canine islets [64]. Islets from seven consecutive canine isolations 
were dissociated into single cells and cryopreserved in 2 M DMSO medium using 
a slow stepwise cooling method (0.25°C/min) to 40°C followed by storage in 
−196°C. Following rapid thawing (200°C/min), 81.5% of cryopreserved islets were 
recovered with no significant difference in insulin stimulation index (SI) when 
compared to non-treated canine islets (10.5 A.U. versus 12.4 A.U. respectively) [64]. 
Another study sought to standardize the critical removal process of DMSO from 
islet medium during the thawing phase. This protocol involves the slow stepwise 
addition of sucrose solution to dilute out the DMSO post-thawing [64]. Overall, 
DMSO will continue to play an important role in islet cryopreservation research.
4.2.2 Ethylene/polyethylene glycol
A common constituent of car antifreeze, other permeating CPAs include both 
ethylene and polyethylene glycol, which have been studied for islets cryopreser-
vation [53]. These low-molecular weight substances easily penetrate the cell 
membrane, much like DMSO, and cause solute equilibrium, which osmotically 
drives water toward the extracellular space [38]. Once the use of DMSO as a CPA 
was established in islet cryofreezing, studies in rat islets began to suggest potential 
toxicity issues when DMSO was exposed to rat islets [41, 65]. One study comparing 
DMSO and EG CPAs resulted in DMSO islets that exhibited lower cellular DNA, 
insulin, glucagon, and impaired insulin secretory patterns compared to EG, which 
was more like non-frozen islets. Upon transplantation of each islet group, normal 
glycemic control was achieved in 100% of EG-treated and non-frozen islets but only 
92% of DMSO-treated islets recipients, which also experienced delays in diabetes 
correction [65]. When islets cryopreserved with varying concentrations  
(1, 2, and 3 M) of DMSO, EG, and PG were exposed to islets from canine and 
human sources, the permeability (Ps = μm/s) was quantified. The highest Ps was 
achieved in canine islets when 2 M EG (2.47 μm/s) was used while 2 M PG showed 
the highest Ps in human islets (3.48 μm/s) suggesting potential use of EG and PG in 
islet cryopreservation [66].
4.2.3 Permeating CPA mixtures
Attempts have been made to produce mixtures of DMSO and EP (30% EP, 20% 
DMSO) for use during vitrification phase, which can help reduce the toxicity risks 
of using DMSO alone. A mixture of ethylene glycol (EG) and DMSO, classified 
as EDT324, was used as a cryoprotectant during the cooling phase with rat islets. 
EDT324-treated cryopreserved islets showed significant increases in islet viability 
and insulin secretory capability compared to use of DMSO (10%) alone [67]. 
EDT324-treated islets were then transplanted into allogenic rat recipients and dia-
betic correction was achieved after 2 days. Similar results were observed after islets 
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were treated with one of two EG/DMSO mixtures (1 M ME2SO + 1 M EG, or 1 M 
ME2SO + 0.5 M EG). Islets treated with permeating CPA mixtures achieved signifi-
cantly higher yield and viability compared to islets treated with DMSO only. When 
transplanted into STZ-induced mice, islets treated with DMSO/EG mixtures caused 
normoglycemia 12 days faster on average than DMSO only-treated islets [68].
4.3 Non-permeating cryoprotective additives
4.3.1 Saccharides
Although permeating cryoprotectants have been mainly used during mam-
malian cell cryopreservation, saccharides have demonstrated survival advantages 
when added to the vitrification medium. When adult human islets were treated 
with 300 mmol/L trehalose, a 92% recovery rate was achieved compared to 58% 
recovery of DMSO-treated islets in addition to 14-fold increase in insulin content 
within islet grafts. More prominent differences in recovery were observed in fetal 
human islets treated with trehalose compared to islet only treated with DMSO [69]. 
More recently, an antifreeze glycoprotein (AFGP) was included to DMSO slow 
cooling phase medium during cryofreezing of rat islets. When compared to DMSO 
only protocol, AFGP-treated islets demonstrated significant increases in recovery 
rate (85 ± 6.25 versus 63.3 ± 14.2%) and insulin stimulation index (3.86 ± 0.43 
versus 2.98 ± 0.22) were observed [70]. These results demonstrate that saccharides 
and saccharide-containing substances can be used in conjunction with lower DMSO 
concentrations and help reduce islet toxicity.
4.3.2 Polymeric compounds
High-molecular weight polymeric compounds such as polyvinylpyrrolidone 
(PVP) and dextran have been shown to be effective at formation of amorphous 
glass matrix during cryofreezing phase [71]. When 10% PVP was added to 
cryopreservation medium before cooling phase, rat islet recovery and function 
were significantly higher than when islets were treated with 2 M DMSO and 3 M 
glycerol. Islets treated with 2 M PG demonstrated comparable islet recovery and 
function to PVP-treated group [72]. Although, the use of high-molecular weight 
cryoprotectants has been observed, past studies suggest that these compounds are 
ineffective at slow cooling temperature transitions, which is a crucial step of the 
cryofreezing process [71].
4.4 Other potential CPAs
One of the most important causes of cell damage/death during cryopreserva-
tion is due to ice crystal formation. However, there are unavoidable damaging 
consequences to islet health when islet cells, especially when in multicellular tissues 
fragments, are exposed to subfreezing temperatures (≥100°C), which can lead to 
apoptosis and/or necrosis after the post-thawing phase of cryopreservation [73]. 
Due to its fragile multicellular tissue structure, islet fragments are susceptible to 
various stresses including oxidative stress, osmotic stress, hypoxia, hypothermia, 
and inflammation induced by the cryopreservation process, which can have acute 
and/or long-term effects on islet graft viability and function [74, 75]. As research 
into islet cryoprotection has become more nuanced in recent years, studies have 
started to target CPAs, which reduce stress-induced cell death associated with the 
cryopreservation process (Table 1).
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4.4.1 Butylated hydroxyanisole (BHA)
Oxidative stress in cells produces endogenous reactive oxygen species (ROS), 
such as superoxide (O2
−) and free hydroxyl (OH−), which leads to an increase in 
free radical concentration intracellularly [76]. Elevated internal levels of free radi-
cals can cause cellular damage and lead to cellular process disruptions. To combat 
cryopreservation-related oxidative stress, one early study added butylated hydroxy-
anisole (BHA) to islet cryomedium while monitoring oxidative stress via gluta-
thione redox state (GSH/GSSG). Islets treated with BHA demonstrated enhanced 
insulin secretory behavior (2.2-fold increase) when compared to untreated islets. In 
addition, exposure to alloxan, a highly damaging free radical generating agent, did 
not induce significant oxidative stress [77].
4.4.2 Ascorbic acid-2 glucoside (AA2G)
Ascorbic acid-2 glucoside (AA2G), a derivative of Vitamin C, is a potent 
antioxidant and can deliver stable antioxidant activity into culture media [78]. 
AA2G (100 μg/mL) in combination with the UW islet preservation solution 
was used as the cryopreservation medium [79, 80]. Following 3 months of 
storage (−80°C), the islets treated with UW/AA2G demonstrated viability 
maintenance (68.3 ± 5.6%) and significantly increased insulin stimulation via 
glucose-stimulated insulin secretion (GSIS) test, when compared to treatment 
with UW alone (1.93 ± 0.5 and 1.17 ± 0.6 respectively). Transplantation of 
thawed AAG2/UW-treated into liver of nude mice produced engraftment with 
insulin-positive cells observed.
4.4.3 Curcumin
Curcumin, the main component of turmeric spice, has demonstrated anti-
oxidant and anti-inflammatory effects in multiple cell types [81]. Curcumin has 
not been shown to increase insulin stimulation; however, it has demonstrated 
upregulation of oxidative stress-reducing genes Hsp70 and HO-1 [47]. To evaluate 
cyroprotective abilities of curcumin, Kanitkar et al. compared the effect of 10% 
DMSO with and without 10 μM curcumin on islets treated with slow cooled cryo-
preservation (−196°C) for 7 days. Curcumin-treated islets showed increases in SI 
compared to non-treated cryopreserved islets but no difference from fresh islets. 
Parameter Method Reference
Cryoprotectant EPA + DHA + Metformin [40]
Cooling rate Rapid (50–70°C/min) [27–29]
Thawing rate Rapid (150–200°C/min) [32]
Oxygen environment 50% during thawing [54]
3D structure Freeze as individual cells, re-aggregate into spheroids after 
thaw
[51]
Encapsulation 1.75% Alginate encapsulation prior to cryopreservation [64]
Assessment methods include islet viability, glucose sensitivity, and GSIS values after thawing.
Table 1. 
Cryoprotection: A quick summary of the parameters that had the best outcome for the islets during 
cryopreservation.
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In curcumin-treated medium, over-expression of HO-1 and Hsp70 was observed to 
incrementally increase as the cryopreservation process unfolded [47].
4.4.4 Taurine
An amino sulfonic acid, taurine has been suggested as a CPA because of chemical 
properties that allow antioxidant and osmoregulatory properties [82]. An addition 
of taurine to the cryopreservation medium demonstrated cyroprotective effects 
during islet cryopreservation (Hardikar 2001). Pretreatment of taurine prior to 
cryopreservation freezing phase at 0.3 mM and 3.0 mM resulted in high maintained 
viability of 91.9 ± 2.3 and 94.6 ± 1.58% respectively. Lipid peroxidation, which 
is a known indicator of oxidative stress, was reduced significantly compared to 
controls. Finally, normoglycemia was achieved when taurine-treated cryopreserved 
islets were transplanted into immunocompetent mice.
4.4.5 Γ-aminobutyric acid (GABA)
GABA neurotransmitters facilitate the inhibitory neuronal pathways within 
the central nervous system and have demonstrated regulatory and protective 
effects on β-cells [83]. GABA has been shown to produce membrane polarization 
(Ca2+-influx) which activates survival and growth pathways (PI3-K/Akt) and can 
restore β-cells’ mass in severely diabetic mice [83, 84]. Islets were treated with 50 or 
100 μM GABA and were cryopreserved to 196°C for up to 30 days. At both 15 and 
30 days post-thawing, islets treated with GABA exhibited similar insulin secretory 
behavior compared to fresh islets. When oxidative stress was measured via MTT 
assay, reduced ROS content was observed in GABA-treated islets in comparison to 
non-treated cryopreserved islets [46].
4.4.6 Metformin
Metformin is a standard-of-care drug used for the treatment of Type 2 Diabetes 
and has been identified as an “essential medicine” by the WHO [85]. While the 
complete mechanism of action is unknown for metformin, it has demonstrated 
insulin-sensitizing properties and reduces unfettered liver gluconeogenesis [86, 
87]. When used as a cryoprotective agent at ultralow temperatures, metformin 
produced membrane stabilizing effects. Cryopreserved islets treated with metfor-
min-containing cyromixtures exhibited comparable viability (90 versus 100%) 
to non-treated fresh islets. Improved insulin secretion was observed at 15 days 
post-thawing (8 ng/mL) with a stimulation index value of >5, suggesting islets were 
highly functional [46]. Recently, similar cyroprotective results were observed in 
chicken islets [88].
4.4.7 Sericin
Produced by Bombyx mori silkworm, this gel-like protein has previously dem-
onstrated oxidative stress reduction properties induced by freezing temperatures 
in both rat islets and various other mammalian cell lines [89, 90]. When added 
to media, Ahnishi et al. showed no significant differences between GSIS results 
between the FBS + DMSO and the sericin + DMSO groups. This study demonstrated 
that reduction in DMSO content in cyromixtures is possible with addition of 1% 
sericin, which could reduce the toxic risk posed by high concentrations of DMSO.
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4.5 Recent advances in islet cryopreservation technology
4.5.1 Cryopreservation with alginate-based microencapsulation technology
Alginate-based microencapsulation technologies have developed in con-
cert with islet transplantation research where the alginate polymer forms a 
semipermeable immune-isolating barrier around islet fragments [91–93]. 
Alginate-microencapsulation has recently been applied to the field of islet 
cryopreservation in order to characterize its effect on islet survivability [33]. 
Chen et al. reported the development of an oxygen-sensing alginate coating to 
encapsulate islets prior to cryopreservation [94, 95]. Islets were encapsulated 
with alginate coating containing ruthenium-based oxygen-sensitive fluorophore 
(ROF) after which the encapsulated islets were subjected to a 10% DMSO with or 
without 50x10−3 M trehalose and stored for 1–7 days. Encapsulated islets under-
going cryopreservation showed significantly higher insulin stimulation behavior 
than bare islets at Day 1 and 7 [94]. In addition to cyroprotective abilities, the 
microcapsules treated with ROS demonstrated viable oxygen sensitivity during 
OCR measurements. This study demonstrates the use of multiple cyroprotective 
parameters to mitigate potential damage during cryopreservation [94]. Other 
studies have demonstrated the benefits of alginate microencapsulation use 
during cryopreservation as the 3D barrier is porous and can resist stress/strain 
associated with ice formation [94, 96, 97].
4.5.2 Hollow fiber vitrification
Previously described for use in embryological studies, vitrification scaffolds 
have been suggested as a medium for cryopreservation of islets to improve the islet 
survival [98, 99]. This technique involves the loading of islets into a hollow fiber 
chamber (HFV) composed of cellulose-triacetate, which is permeable to CPAs 
[100]. Researchers used a combination of permeating CPAs like DMSO and EG dur-
ing cooling phase of both non-vitrified islets and islets vitrified using HFV method. 
In Vitro assays demonstrated similar islet structure and insulin gene promoter 
expression (NeuroD, Pdx1, MafA) to non-vitrified islets; however, the insulin 
stimulation index was significantly decreased for islets undergoing HFV compared 
to non-vitrified islets (27.8 ± 8.2 and 3.5 ± 0.6 respectively). Nonetheless, after HVF 
and non-vitrified islets were transplanted into kidney subcapsular space, all mice 
were euglycemic within 4–8 days and remained so for 1 month until nephrectomy, 
which induced hyperglycemia.
5. Conclusion
Islet cryopreservation has come a long way in the last 40 years. Many 
parameters of cryopreserving islets are being actively researched because of the 
high demand for long-term storage. Currently, entire organ cryopreservation 
is not entirely feasible, and is only shown possible after a few hours of storage 
[101]. Based on experiments performed in our lab along with results from other 
research groups, we predict that future improvements in islet cryopreservation 
will rely on the use of a mixture of cyroprotective additives along with the use 
of secondary technologies like alginate encapsulation [96]. We hope that with a 
standardized cryopreservation protocol, islet banking would be more feasible, 
and ultimately, transplantation would no longer be throttled by the donor-
recipient mismatch.
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